Literature DB >> 29379540

Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis.

Andrzej Wędrychowicz1, Przemysław Tomasik2, Andrzej Zając3, Krzysztof Fyderek1.   

Abstract

INTRODUCTION: Interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1ra) and interleukin-6 (IL-6) contribute to the pathogenesis of ulcerative colitis (UC). The aim of our study was to evaluate the serum and stool IL-1β, IL-1ra and IL-6 concentrations as potential prognostic factors in children with UC.
MATERIAL AND METHODS: Thirty-eight children with UC (20 active, 18 inactive) and 14 healthy controls were prospectively included in the study. IL-1β, IL-1ra and IL-6 concentrations were measured in serum and stool supernatants at inclusion to the study using ELISA immunoassays. The children were followed up over 5 years, and at each follow-up clinical disease activity, quantity and severity of relapses, nutritional status, endoscopic and histopathologic activity, disease complications and the treatment regimen were evaluated.
RESULTS: In children with active and inactive UC who had relapsed during a 5-year follow-up period compared to the non-relapse groups we found significantly increased serum IL-1β (1.34 vs. 0.98 pg/ml, p < 0.05, and 1.02 vs. 0.68 pg/ml, p < 0.01, respectively,) and IL-1ra (718.0 vs. 453.2 pg/ml, p < 0.05, and 567.4 vs. 365.1 pg/ml, p < 0.01, respectively). Additionally, in children who had experienced complications during a 5-year follow-up period we observed significantly increased serum and stool IL-1β (p < 0.05) and serum IL-1ra (p < 0.01) compared to the group without complications.
CONCLUSIONS: We concluded that serum IL-1β and IL-1ra and to a lesser extend stool IL-1β concentrations may be useful prognostic factors in children with active and inactive UC over a short-term follow-up period, which may help to identify children that require more aggressive therapy due to an increased risk of relapse or complications resulting from UC.

Entities:  

Keywords:  children; complication; interleukin; relapse; ulcerative colitis

Year:  2017        PMID: 29379540      PMCID: PMC5778426          DOI: 10.5114/aoms.2017.68696

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


  38 in total

1.  Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease.

Authors:  Krzysztof Fyderek; Magdalena Strus; Kinga Kowalska-Duplaga; Tomasz Gosiewski; Andrzej Wedrychowicz; Urszula Jedynak-Wasowicz; Małgorzata Sładek; Stanisław Pieczarkowski; Paweł Adamski; Piotr Kochan; Piotr B Heczko
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

2.  Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria.

Authors: 
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-07       Impact factor: 2.839

Review 3.  Interactions between the host innate immune system and microbes in inflammatory bowel disease.

Authors:  Clara Abraham; Ruslan Medzhitov
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

4.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

5.  High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis.

Authors:  Y R Mahida; L Kurlac; A Gallagher; C J Hawkey
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

6.  Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

Authors:  S Dionne; I D D'Agata; J Hiscott; T Vanounou; E G Seidman
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

Review 7.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

8.  Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.

Authors:  Nevin Oruç; Omer Ozütemiz; Necla Osmanoğlu; Tankut Ilter
Journal:  Turk J Gastroenterol       Date:  2009-03       Impact factor: 1.852

9.  Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.

Authors:  V Casini-Raggi; L Kam; Y J Chong; C Fiocchi; T T Pizarro; F Cominelli
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

10.  Cytokine profiling in exhaled breath condensate after exercise challenge in asthmatic children with post-exercise symptoms.

Authors:  Paweł Majak; Joanna Jerzyńska; Magdalena Bojo; Agnieszka Brzozowska; Magdalena Koczkowska; Piotr Sielski; Włodzimierz Stelmach; Rafał Stelmach; Anna Janas; Iwona Stelmach
Journal:  Arch Med Sci       Date:  2016-07-01       Impact factor: 3.318

View more
  5 in total

1.  Sphk1 promotes ulcerative colitis via activating JAK2/STAT3 signaling pathway.

Authors:  Jiawen Liu; Bo Jiang
Journal:  Hum Cell       Date:  2019-10-12       Impact factor: 4.174

2.  NGS study of glucocorticoid response genes in inflammatory bowel disease patients.

Authors:  Marzena Skrzypczak-Zielinska; Marcin Gabryel; Daria Marszalek; Agnieszka Dobrowolska; Ryszard Slomski
Journal:  Arch Med Sci       Date:  2019-05-05       Impact factor: 3.318

3.  Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19.

Authors:  Graham J Britton; Alice Chen-Liaw; Francesca Cossarini; Alexandra E Livanos; Matthew P Spindler; Tamar Plitt; Joseph Eggers; Ilaria Mogno; Ana S Gonzalez-Reiche; Sophia Siu; Michael Tankelevich; Lauren Tal Grinspan; Rebekah E Dixon; Divya Jha; Adriana van de Guchte; Zenab Khan; Gustavo Martinez-Delgado; Fatima Amanat; Daisy A Hoagland; Benjamin R tenOever; Marla C Dubinsky; Miriam Merad; Harm van Bakel; Florian Krammer; Gerold Bongers; Saurabh Mehandru; Jeremiah J Faith
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

4.  Acute mesenteric lymphadenitis in children: findings related to differential diagnosis and hospitalization.

Authors:  Mustafa Yaşar Özdamar; Erdal Karavaş
Journal:  Arch Med Sci       Date:  2018-11-08       Impact factor: 3.318

5.  Psoriasis Is Associated With Elevated Gut IL-1α and Intestinal Microbiome Alterations.

Authors:  Sergey Yegorov; Dmitriy Babenko; Samat Kozhakhmetov; Lyudmila Akhmaltdinova; Irina Kadyrova; Ayaulym Nurgozhina; Madiyar Nurgaziyev; Sara V Good; Gonzalo H Hortelano; Bakytgul Yermekbayeva; Almagul Kushugulova
Journal:  Front Immunol       Date:  2020-10-01       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.